Sector News

Haemonetics Expands Executive Management Roles To Complement Global Growth Strategy

April 28, 2015
Life sciences
/PRNewswire/ – Haemonetics Corporation announced today expanded roles for two executives.  These changes are part of an ongoing plan to advance the Company’s global leadership in blood management solutions and to execute on strategies to enhance shareholder value.
 
Kent Davies, who joined the Company in 2014, is appointed to the new position of Chief Operating Officer, reporting directly to Brian Concannon, President and CEO.  In this expanded role, Mr. Davies will have overall accountability for the Company’s commercial, product development and product management focus across the entire portfolio and in all geographies. 
 
Byron Selman, who joined the Company upon the acquisition of Pall Corporation’s transfusion medicine business in 2012, is appointed to the position of President, Global Markets, reporting to Mr. Davies.  Mr. Selman will oversee the Company’s global commercial and market development efforts, with the exception of the Company’s commercial Plasma business. 
 
Mr. Concannon stated: “Haemonetics enters fiscal 2016 with good momentum, brought about by recent contract wins, new product innovations and launches, and a Comprehensive Blood Management Solutions (CBMS) offering that is gaining traction with customers.  These two management promotions will enhance our execution efforts and strategic focus in all of our markets, while leveraging our strengths in product management and product development.”
 
Source: Haemonetics

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend